PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2039044
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2039044
Bone Tumor Ablation Devices Market is estimated to be valued at USD 111.0 Mn in 2026 and is expected to reach USD 219.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 111.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.20% | 2033 Value Projection: | USD 219.3 Mn |
Tumor ablation is a minimally invasive procedure to remove the tumor cells or tissue from the body. Tumor ablation devices consist of a catheter, which is introduced into the tumor under imaging guidance. The use of microwave ablation magnetic image-guiding systems has provided an effective adjunct in laparoscopic ablation, provided better support to surgeons, and increased patient outcomes. Key players are also focused on launching of ablation devices, which is expected to drive the market growth over the forecast period. For instance, in January 2016, Medtronic Plc. launched the OsteoCool radiofrequency ablation system in the U.S. OsteoCool RF Ablation system is a cooled radiofrequency (RF) ablation technology. It offers simultaneous, dual-probe capabilities for treating painful bone tumors.
Osteoporosis is a common cause for bone fractures and its prevalence gradually increases with age. For instance, according to the National Center for Biotechnology Information, osteoporosis occurs in 10% men and 13% in women, who are aged 60 years or above. According to the National Osteoporosis Foundation data of 2014, a total of 54 million U.S. adults aged 50 and older were affected by osteoporosis and low bone mass in 2013. It further states that the number of bone fractures will increase by 2 to 4 times by 2020 and 41 million women will suffer from osteoporosis or osteoarthritis. This is mainly attributed to significant rise in geriatric population.
Furthermore, key players in the market are focusing on development of technologically advanced bone tumor ablation devices for treatment of highly prevalent cancer cases and launch them in the market. For instance, in 2018, doctors at Johns Hopkins Medical Center, Baltimore, Maryland reported successful use of AveCure microwave ablation system for the treatment of Metastatic Bone Cancer spinal tumors. Moreover, in 2018, doctors at a major hospital in Guadalajara, Mexico reported successful use of AveCure microwave ablation system for the treatment of brain tumors.